Skip to main content

Table 2

From: Pneumococcal colonization and carriage

Age group

Pneumococcal Serotypes

Carriage

Invasive Pneumococcal Disease

Expected IPD

n (%) colonized Pre-Vaccine (2007–2009): Period-1

n (%) colonized Post-vaccine (2012): Period-2

Relative Risk (95% CI)

Average Incidence (per 100000) 2005 to 2008: Period-1

Incidence (per 100000) 2012: Period-2

Incidence risk reduction (95% Confidence Interval)

Incidence (per 100000)a

Children (0–2 years)

7-valent-6A

661 (35.9)

88 (11.2)

0.31 (0.25–0.38)

149.0

14.5

0.10 (0.06–0.17)

46.5

1,3,5,7F,19A

65 (3.5)

23 (2.9)

0.83 (0.52–1.32)

32.1

8.3

0.26 (0.12–0.55)

26.6

NVT

370 (20.1)

337 (42.8)

2.13 (1.89–2.41)

37.7

37.3

0.99 (0.63–1.56)

80.3

All pneumococcal

1096 (59.5)

448 (56.9)

0.96 (0.89–1.03)

220.9

60.2

0.27 (0.20–0.36)

211.2

Women (15 to 45 years)

7-valent-6A

129 (7.0)

22 (1.4)

0.20 (0.13–0.32)

13.5

3.8

0.28 (0.09–0.87)

2.7

1,3,5,7F,19A

41 (2.2)

27 (1.8)

0.79 (0.49–1.28)

11.7

6.3

0.54 (0.20–1.42)

9.6

NVT

175 (9.5)

127 (8.3)

0.87 (0.70–1.08)

7.1

9.7

1.36 (0.52–3.58)

6.2

All pneumococcal

345 (18.7)

176 (11.5)

0.61 (0.52–0.73)

32.3

19.8

0.61 (0.35–1.07)

19.9

  1. aThe expected IPD is equal to the proportion of post vaccine carriage prevalence and pre-vaccine carriage prevalence multiplied by the pre-vaccine IPD incidence